Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Correlation between ctDNA level and recurrence-free survival (RFS)
研究概览
简要总结
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a first diagnosis of HCC.
- •Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy.
- •Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level.
排除标准
- •Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma.
- •Any other concurrent malignancy.
- •History of organ transplant or hepatic encephalopathy.
结局指标
主要结局
Correlation between ctDNA level and recurrence-free survival (RFS)
时间窗: 1 years
ctDNA measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
Correlation between specific plasma protein expression level and recurrence-free survival (RFS)
时间窗: 1 years
plasma proteomic measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
次要结局
- Correlation between tumor mutation numbers and recurrence-free survival (RFS)(1 years)